Clinical trials: Elderly Population
COVID-19
Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to…
- Trial name
- NCT05003479
- Testing
- SARS-CoV-2 Vaccine (Vero Cells), Inactivated
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Shenzhen Kangtai Biological Products Co., LTD
SARS CoV-2 Infection, Elderly
Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly
The objective of this trial is to evaluate the effect of the consumption of a probiotic strain on the incidence and severity of COVID-19 in elderly population living in a nursing home.
- Trial name
- NCT04756466
- Testing
- Lactobacillus
- Where
- 3 sites in Spain
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Biosearch S.A.
Age Related Macular Degeneration
Mobile Clinic - a Cross-sectional Epidemiological Survey
The aim of the study is to find out prevalence of aged-related macular degeneration (AMD) in Slovak Republic. The outcome of the project will be epidemiology survey, prevalence of wet form of AMD in relation to demographic data…
- Trial name
- NCT02055612
- Where
- Slovakia
- Volunteers
- 3,278 people, healthy volunteers welcome
- Sponsor
- Novartis Slovakia, s.r.o.
COVID-19
A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04756323
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Norovirus
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
The purpose of this study is to further develop a formulation and dose regimen of the norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe in an elderly population aged 60 years and above.
- Trial name
- NCT02661490
- Testing
- Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline)
- Where
- 10 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Male and Female Subjects
Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio
The study has been designed as a randomised, parallel-group, double-blind, 3 arm study to investigate the comparative pharmacokinetics, safety, immunogenicity and tolerability between AVT80 and Entyvio in healthy volunteers.
- Trial name
- NCT06732804
- Testing
- AVT80, Geographical region 1 Entyvio, Geographical region 2 Entyvio
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Alvotech Swiss AG
Cystic Fibrosis
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
The purpose of this study was to evaluate the safety and efficacy of ivacaftor in participants with cystic fibrosis (CF) who were aged 12 years or older and were homozygous for the F508del-CF transmembrane conductance regulator…
- Trial name
- DISCOVER (NCT00953706)
- Testing
- Ivacaftor
- Where
- 34 sites in United States
- Volunteers
- 140 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Healthy
Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446
This study is designed to evaluate the safety, tolerability and PK of AZD1446 in Subjects when given as multiple dose administration for either 7 Days (Day 1 single dose, Day 2-6 multiple doses) in Part A and optionally at…
- Trial name
- NCT00902993
- Testing
- AZD1446
- Where
- 2 sites in Sweden
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition…
- Trial name
- NCT04531462
- Testing
- Empagliflozin
- Where
- 18 sites in Japan
- Volunteers
- 129 people
- Sponsor
- Boehringer Ingelheim
Tuberculosis, TB Infection
A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations
A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia
- Trial name
- NCT07647107
- Testing
- LipovaxinS4-EAH (Middle Dose), LipovaksinS4-EAH (High Dose)
- Where
- Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer
COVID-19, Coronavirus Infections
Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) Phase III Clinical Trial
This clinical trial adopts a randomized, double-blind and placebo-controlled design. A total of 16000 participants are planned to be enrolled, of which, Cohort 1: 15000 participants vaccinated with ≥2 doses of inactivated…
- Trial name
- NCT05599516
- Testing
- LIBP-Rec-Vaccine, BIBP-Rec-Vaccine
- Where
- United Arab Emirates
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Virus Diseases, RNA Virus Infections
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population
This is a multiple sites phase II trial, randomized, observer-blind, dose ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-based Seasonal VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02236052
- Testing
- Non-adjuvanted low dose of quadrivalent VLP vaccine, Non-adjuvanted medium dose of quadrivalent VLP vaccine, Non-adjuvanted high dose of quadrivalent VLP vaccine
- Where
- 3 sites in Canada
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population
As influenza vaccine efficacy is reported to be lower in elderly subjects compared to healthy adults, probably as a result of immunosenescence, there is a desire to devise ways to increase the current vaccines efficacy for this…
- Trial name
- NCT00318149
- Testing
- Fluarix, Fluarix-AS25, Fluarix-AS50
- Where
- Belgium
- Volunteers
- 425 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451013 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-2 (NCT03575871)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 391 people
- Sponsor
- Pfizer
Hyperemia
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants.
- Trial name
- NCT01959243
- Testing
- Brimonidine Tartrate, Vehicle, Sodium Fluorescein
- Where
- 4 sites in United States
- Volunteers
- 507 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Insomnia
Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder.
- Trial name
- NCT05423717
- Testing
- Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg
- Where
- 35 sites in United States, Bulgaria and 4 more
- Volunteers
- 166 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
COVID-19
A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above
This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years…
- Trial name
- COVID-19 (NCT04510207)
- Testing
- Inactivated SARS-CoV-2 Vaccine (Vero cell)
- Where
- 6 sites in Bahrain, Egypt and 2 more
- Volunteers
- 44,101 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Sleep Initiation and Maintenance Disorders
Efficacy Study of EVT 201 in the Treatment of Elderly Patients With Daytime Sleepiness
The purpose of this study is to determine whether a compound known as EVT 201 is effective in treating elderly patients diagnosed with primary insomnia who also have moderate daytime sleepiness.
- Trial name
- NCT00401284
- Testing
- EVT 201
- Where
- 22 sites in United States
- Volunteers
- 135 people
- Sponsor
- Evotec Neurosciences GmbH
Asthma
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients
This is a comparator study to assess safety and efficacy of Flutiform compared with Fluticasone pMDI and Seretide pMDI in paediatric asthma patients with moderate to severe persistent, reversible asthma.
- Trial name
- NCT01511367
- Testing
- Flutiform, Seretide, Flixotide
- Where
- 8 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 498 people
- Sponsor
- Mundipharma Research Limited